Companies hope to have next generation of vaccines against emerging variants by next year
GlaxoSmithKline and Germany’s CureVac have reached a €150m (£132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic.
The two companies said they plan to work jointly to develop a vaccine that can address “multiple emerging variants in one vaccine”.
